Immune Design Corp. (IMDZ) Stock Analyst Ratings
NASDAQ:IMDZ - Nasdaq -
ChartMill assigns a Buy % Consensus number of 67% to IMDZ. The Buy consensus is the weighted average rating of the current analysts ratings.
IMDZ was analyzed by 6 analysts. The buy percentage consensus is at 67. So analysts seem to be have mildly positive about IMDZ.
In the previous month the buy percentage consensus was at a similar level.
IMDZ was analyzed by 6 analysts. More opinions would make the average more meaningful.